Marc Beer Founder of Renovia
Renovia, co-founded by Mark Beer, will proceed with new products after it closed a $ 32 million series B on Tuesday. The plan will progress despite a $ 10 million debt risk. Boston-based Matt Technology researchers estimate that 250 million women treated with pelvic floor diseases, such as urinary incontinence worldwide, are affected. Renovia’s first product, Leva, was approved by the FDA in April.
The Longwood Fund, an investment firm in healthcare invested in Renovia. The series B round was led by Perceptive Advisors from New York, and Ascension ventures Missouri-based firm. The funding will be used to develop and test four therapeutic and diagnostic products, including a new generation of Leva devices.
Investors in Healthcare
Marc Beer stated that healthcare deserves the support of these leading groups of healthcare investors who, like them, want to diagnose better, treat and improve the lives of millions of women affected by pelvic floor disease. By combining innovative and exclusive sensor technology and a form factor with digital health platforms, customers can gain valuable data, and get new treatment options.Patients will be aware and understand pelvic floor disease, therefore, reducing costs.
Renovia is Mr. Beer’s first company since 2015. Marc Beer is also a strategic advisor to OvaScience. The Waltham biotechnology announced this month that it will merge with Millendo Therapeutics based in Michigan.
Marc Beer’s Career Background
Marc Beer has over 25 years of experience in the growth and commercializing of biotechnology, equipment in pharmaceuticals, and diagnostics. In August 2016, he founded Dr. Ramon Iglesias, Yolanda Lorié and Renovia, and completed the series A financing of leading medical insurance venture capital funds. In 2000, he became the CEO of VIACAC, a biotech company that specialized in the assortment, storage, and in umbilical-cord blood stem cells development. Years under the leadership of Marc, the company employees increased to 300. It was later bought by PerkinElmer – NYSE: PKI, in 2007.
Marc Beer served as the CEO of ViaCell, and also served as a board member of Erytech Pharma. Before joining ViaCell, he was at Genzyme. He served as the vice president of global marketing, and he was given the role of launching several products for people with rare diseases around the world. New York Stock Exchange: ABT. Marc Beer is a former member of the Massachusetts Scientific Committee-MSC and works for the organization of the Biotechnology Industry Organization.
He is the chairman of the Compensation Committee-CC, and a member of the Minerva and Neuroscience Audit Committee, NASDAQ- NERV. He is a member of the Advisory Committee-AC, of the University of Miami-ACUM, and a member of the Notre Dame Research Marketing Advisory Board-NDRMAB, and the Research Advisory Committee of Noordam High School. Marc Beer holds a BS from the University of Miami. Learn more: https://renoviainc.com/leadership/